How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Do you agree on the proposal for withdrawing this technology appraisal? If not, please can you state why you disagree.

  • Question on Consultation

    Are you aware of any implications for UK clinical practice on withdrawing this technology appraisal? If so, please describe.

2025 surveillance of electroconvulsive therapy (technology appraisal guidanceTA59, NICE guideline NG222, NICE guideline CG178, NICE guideline CG185, NICE guideline CG192)

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

Population impact

According to a press release from the Royal College of Psychiatrists in December 2023, 1,835 adults received electroconvulsive therapy in 2021 across England, Wales, and Ireland. The report indicated that these patients received acute ECT across 85 mental health clinics during that period. This data came from the ECTAS dataset report (from 1st January to 31st December 2021), one of the most comprehensive ECT datasets globally.

According to the Office for National Statistics (ONS) report for mental health, around 21% of adults in Great Britain reported experiencing depression in autumn 2022. Schizophrenia has a lifetime prevalence of approximately 0.3% to 0.7% in the UK, while bipolar disorder affects around 1% to 2% of the population, equating to roughly 1.3 million people. Prevalence data for catatonia is limited, as it typically occurs alongside other mental health conditions.